Developer docs
API playgroundTry for free, no card

Search company profiles

Lambda Biologics

Full company profile

uuid003two9

Namestring
Lambda Biologics
Legal namestring
Lambda Biologics GmbH
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Lambda Biologics GmbH is a privately held German contract research organization headquartered in Leipzig that provides organoid-based in vitro testing services for drug discovery, disease modeling, and non-animal safety assessment. The company's core offering is built on a patient-derived organoid platform that generates three-dimensional cell culture models preserving tumor heterogeneity and patient-specific genetic alterations, combined with immune cell and stromal cell integration (TILs, cytotoxic T cells, regulatory T cells, macrophages, CAFs) to recreate tumor microenvironments for immuno-oncology evaluation. A registered patent on TIL + organoid co-culture methodology for anticancer drug efficacy testing is positioned by the company as globally unique, and the offering extends to a curated organoid biobank, the MyLab cloud platform for project management and data analysis, and supporting technical services in molecular biology, bioinformatics, spatial biology, and live 3D imaging. The customer base spans pharmaceutical and biotechnology companies (drug discovery, immunotherapy evaluation, ADC efficacy testing), cosmetics firms (non-animal testing for K-Beauty), food industry players (functional ingredient and probiotic testing via ODISEI-Gut), and academic and clinical research institutions across Korea, Germany, the US, and Australia.

The company monetizes through a project-based CRO model with per-assay pricing ranging from approximately €6,000 (cytotoxic T cell co-culture) to €9,057+ (TIL service), supplemented by a recurring-access organoid banking system. Go-to-market is sales-led via direct quote requests through the MyLab platform, conference engagement (AACR 2026 Booth 1603, ODC26 Seoul, IFSCC 2026), and content marketing across LinkedIn, YouTube, Instagram, and a company blog. Recent commercial activity includes four product launches in the first half of 2026 across immuno-oncology, ADC evaluation, gut health, and CAF co-culture, indicating active expansion of the service catalog rather than evidence of scaled recurring enterprise revenue.

Short descriptiontext

Lambda Biologics GmbH is a German contract research organization offering patient-derived organoid and tumor-microenvironment co-culture services for drug discovery, immunotherapy evaluation, cosmetics testing, and academic research, serving pharma, biotech, cosmetics, and academic clients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLeipzig, Germany
HQ citystring
Leipzig
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organoid drug testing, preclinical contract research, patient-derived organoids, tumor microenvironment modeling, immuno-oncology co-culture
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Organoid Services and Research
TypeProfessional Services
Description

Contract research organization providing organoid-based drug evaluation services to pharmaceutical companies, biotechnology firms, and academic institutions. Services are priced per project or per assay type, with pricing starting from 6,000-9,000+ EUR per service.

afs.lambda-bio.com
2Organoid Banking System
TypeSubscription Recurring
Description

Access to curated library of ready-to-use organoids - standardized, scalable organoids for in vitro research.

afs.lambda-bio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Regulatory T cell co-culture service
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Regulatory T cell + Organoid co-culture: 7500€+ per project

afs.lambda-bio.com
2Tumor-Infiltrating Lymphocyte (TIL) service
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Tumor-Infiltrating Lymphocyte + Organoid co-culture: 9057€+ per project

afs.lambda-bio.com
3Cytotoxic T cell co-culture service
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Cytotoxic T cell + Organoid co-culture: 6003€+ per project

afs.lambda-bio.com
4Organoid Custom Projects
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Custom organoid projects require quote requests - pricing varies by project scope, tissue type, and assays required

afs.lambda-bio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1MyLab
Description

A cloud-based platform for experimental design consultancy, organoid banking system, and data storage/analysis.

afs.lambda-bio.com
+2 more records
Core offering1 text field

Lambda Biologics is a contract research organization providing organoid-based in vitro drug evaluation services and disease modeling. It supplies patient-derived normal and cancer organoids, custom organoid co-culture assays with immune and stromal cells, and analytical services (molecular biology, bioinformatics, spatial biology, live 3D imaging), delivered through direct project engagements quoted via its MyLab platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Results delivered in less than one month for CRC organoid projects
+1 more record
Product overview1 text field

Lambda Biologics is a specialized contract research organization (CRO) offering organoid-based in vitro solutions for drug discovery and disease modeling. The company's portfolio is organized into three main service pillars: (1) Organoid Service covering normal organoids (lung, gastric, liver, midbrain, cerebral, retinal, adenoid), cancer organoids (colorectal, lung, pancreatic, breast, gastric, ovarian, endometrial, hepatocellular carcinoma), and disease modeling; (2) Research Service including cosmetics testing, OECD TG testing, and zebrafish models; and (3) Technical Service encompassing molecular biology, bioinformatics, spatial biology, and live 3D imaging. The platform is supported by MyLab, a cloud-based research platform featuring an organoid banking system, Lambda Cloud for data management, and experimental design consultancy. Advanced immuno-oncology offerings include co-culture services with cytotoxic T cells, tumor-infiltrating lymphocytes (TILs), regulatory T cells, macrophages (M1/M2), and cancer-associated fibroblasts (CAFs) for tumor microenvironment modeling. Additional specialized services include ADC efficacy/toxicity evaluation, MDSC infiltration assays, and the ODISEI-Gut intestinal platform.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

MyLab is Lambda Biologics' proprietary cloud-based platform providing experimental design consultancy, organoid banking system access, and Lambda Cloud for data storage and analysis. It serves as the primary customer interface for project management and service delivery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research partnership for colorectal cancer (CRC) organoid drug development workflows. KAIST researchers utilized Lambda Biologics' CRC organoid platform to validate lomitapide as a potential anticancer therapy, demonstrating organoid-based preclinical validation within integrated drug development workflows.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large global CRO offering extensive preclinical services including organoid-based safety and efficacy testing, alongside broader discovery, safety assessment, and manufacturing services. Comparable as an incumbent offering organoid services within a much wider preclinical portfolio, competing for the same enterprise pharma customers.

TypeBroad incumbent
Description

Danaher-owned provider of high-content imaging and 3D organoid analysis instruments used in organoid-based drug screening workflows. Comparable as an incumbent serving the same pharma/biotech customers with organoid imaging and analysis capabilities adjacent to Lambda's Live&3D Imaging services.

TypeDirect peer
Description

Provider of human iPSC-derived cell models and organoid services for drug discovery, with focus on liver, intestinal, and disease-specific models. Comparable as a specialty organoid CRO serving pharma and biotech with similar disease modeling and toxicity testing offerings.

TypeDirect peer
Description

Swiss-based provider of 3D in vitro models including organoids, microtissues, and spheroids for drug safety and efficacy testing. Directly comparable as a specialty 3D in vitro CRO with overlapping pharma/biotech customer base and similar non-animal testing value proposition.

TypeDirect peer
Description

Global CRO offering patient-derived xenograft (PDX) and organoid-based preclinical oncology services for pharma and biotech. Directly comparable to Lambda Biologics as both provide human-relevant in vitro/ex vivo tumor models for drug discovery, with overlapping customer base in immuno-oncology and ADC evaluation.

6XCell Science
TypeEmerging player
Description

Provider of iPSC-derived neural and disease organoids for neuroscience drug discovery and toxicology. Comparable as a niche organoid CRO with overlap in disease modeling services (neural organoids), targeting similar pharma/biotech and academic customers in specialty indications.

7Cellesce
TypeEmerging player
Description

UK-based company developing scalable organoid expansion technologies for drug discovery and disease modeling. Comparable as an emerging player in patient-derived organoid services with overlapping focus on biobank scalability and pharma partnerships.

TypeEmerging player
Description

Developer of patient-derived tumor organoid platforms for high-throughput drug screening and predictive oncology. Comparable as an emerging player in patient-derived organoid services with overlapping pharma/biotech customer base and similar focus on translational drug response prediction.

9Hubrecht Organoid Technology (HUB)
TypeDirect peer
Description

Pioneer in organoid technology with foundational patents around Lgr5+ stem-cell-derived organoids; offers organoid biobanking, disease modeling, and drug screening services. Directly comparable as a specialty organoid CRO with biobank and disease modeling offerings serving pharma and academic customers.

TypeBroad incumbent
Description

Major life-science tools company providing organoid culture media, reagents, and supporting services used by organoid researchers globally. Comparable as an incumbent enabling the organoid research ecosystem with overlapping pharma and academic customer base, though operating in tools/reagents rather than CRO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lambda Biologics

Preclinical Contract Research Servicesafs.lambda-bio.com

Lambda Biologics GmbH is a German contract research organization offering patient-derived organoid and tumor-microenvironment co-culture services for drug discovery, immunotherapy evaluation, cosmetics testing, and academic research, serving pharma, biotech, cosmetics, and academic clients globally.

What Lambda Biologics does

Lambda Biologics GmbH is a privately held German contract research organization headquartered in Leipzig that provides organoid-based in vitro testing services for drug discovery, disease modeling, and non-animal safety assessment. The company's core offering is built on a patient-derived organoid platform that generates three-dimensional cell culture models preserving tumor heterogeneity and patient-specific genetic alterations, combined with immune cell and stromal cell integration (TILs, cytotoxic T cells, regulatory T cells, macrophages, CAFs) to recreate tumor microenvironments for immuno-oncology evaluation. A registered patent on TIL + organoid co-culture methodology for anticancer drug efficacy testing is positioned by the company as globally unique, and the offering extends to a curated organoid biobank, the MyLab cloud platform for project management and data analysis, and supporting technical services in molecular biology, bioinformatics, spatial biology, and live 3D imaging. The customer base spans pharmaceutical and biotechnology companies (drug discovery, immunotherapy evaluation, ADC efficacy testing), cosmetics firms (non-animal testing for K-Beauty), food industry players (functional ingredient and probiotic testing via ODISEI-Gut), and academic and clinical research institutions across Korea, Germany, the US, and Australia.

The company monetizes through a project-based CRO model with per-assay pricing ranging from approximately €6,000 (cytotoxic T cell co-culture) to €9,057+ (TIL service), supplemented by a recurring-access organoid banking system. Go-to-market is sales-led via direct quote requests through the MyLab platform, conference engagement (AACR 2026 Booth 1603, ODC26 Seoul, IFSCC 2026), and content marketing across LinkedIn, YouTube, Instagram, and a company blog. Recent commercial activity includes four product launches in the first half of 2026 across immuno-oncology, ADC evaluation, gut health, and CAF co-culture, indicating active expansion of the service catalog rather than evidence of scaled recurring enterprise revenue.

Lambda Biologics firmographics

Firmographics
Name
Lambda Biologics
Legal name
Lambda Biologics GmbH
Website
https://afs.lambda-bio.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Lambda Biologics GmbH is a German contract research organization offering patient-derived organoid and tumor-microenvironment co-culture services for drug discovery, immunotherapy evaluation, cosmetics testing, and academic research, serving pharma, biotech, cosmetics, and academic clients globally.
Ownership category
akta.pro rank

Lambda Biologics industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Organoid drug testing
  • Preclinical contract research
  • Patient-derived organoids
  • Tumor microenvironment modeling
  • Immuno-oncology co-culture

Where Lambda Biologics is headquartered

Location

Headquarters

HQ city
Leipzig
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Lambda Biologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Organoid Services and Research: Contract research organization providing organoid-based drug evaluation services to pharmaceutical companies, biotechnology firms, and academic institutions. Services are priced per project or per assay type, with pricing starting from 6,000-9,000+ EUR per service.
  2. Organoid Banking System: Access to curated library of ready-to-use organoids - standardized, scalable organoids for in vitro research.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRegulatory T cell co-culture service
Unit PricingPay-as-you-goTumor-Infiltrating Lymphocyte (TIL) service
Unit PricingPay-as-you-goCytotoxic T cell co-culture service
Unit PricingPay-as-you-goOrganoid Custom Projects

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Lambda Biologics product offering

Product offering

Core offering

Lambda Biologics is a contract research organization providing organoid-based in vitro drug evaluation services and disease modeling. It supplies patient-derived normal and cancer organoids, custom organoid co-culture assays with immune and stromal cells, and analytical services (molecular biology, bioinformatics, spatial biology, live 3D imaging), delivered through direct project engagements quoted via its MyLab platform.

Product overview

Lambda Biologics is a specialized contract research organization (CRO) offering organoid-based in vitro solutions for drug discovery and disease modeling. The company's portfolio is organized into three main service pillars: (1) Organoid Service covering normal organoids (lung, gastric, liver, midbrain, cerebral, retinal, adenoid), cancer organoids (colorectal, lung, pancreatic, breast, gastric, ovarian, endometrial, hepatocellular carcinoma), and disease modeling; (2) Research Service including cosmetics testing, OECD TG testing, and zebrafish models; and (3) Technical Service encompassing molecular biology, bioinformatics, spatial biology, and live 3D imaging. The platform is supported by MyLab, a cloud-based research platform featuring an organoid banking system, Lambda Cloud for data management, and experimental design consultancy. Advanced immuno-oncology offerings include co-culture services with cytotoxic T cells, tumor-infiltrating lymphocytes (TILs), regulatory T cells, macrophages (M1/M2), and cancer-associated fibroblasts (CAFs) for tumor microenvironment modeling. Additional specialized services include ADC efficacy/toxicity evaluation, MDSC infiltration assays, and the ODISEI-Gut intestinal platform.

Differentiator

Problem solved

Functional benefit

Brands

  • MyLab: A cloud-based platform for experimental design consultancy, organoid banking system, and data storage/analysis.
  • ODISEI-Gut
  • ODISEI Platform

Quantifiable outcome

  • Results delivered in less than one month for CRC organoid projects
  • +1 more outcomes

Companies that use Lambda Biologics

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Lambda Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Lambda Biologics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • MyLab PlatformcoreTechnology or IntegrationMyLab is Lambda Biologics' proprietary cloud-based platform providing experimental design consultancy, organoid banking system access, and Lambda Cloud for data storage and analysis. It serves as the primary customer interface for project management and service delivery.
  • KAIST (Korea Advanced Institute of Science and Technology)coreStrategic or Co-development PartnerCollaborative research partnership for colorectal cancer (CRC) organoid drug development workflows. KAIST researchers utilized Lambda Biologics' CRC organoid platform to validate lomitapide as a potential anticancer therapy, demonstrating organoid-based preclinical validation within integrated drug development workflows.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Lambda Biologics competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Large global CRO offering extensive preclinical services including organoid-based safety and efficacy testing, alongside broader discovery, safety assessment, and manufacturing services. Comparable as an incumbent offering organoid services within a much wider preclinical portfolio, competing for the same enterprise pharma customers.
  • Molecular Devices (Danaher): Danaher-owned provider of high-content imaging and 3D organoid analysis instruments used in organoid-based drug screening workflows. Comparable as an incumbent serving the same pharma/biotech customers with organoid imaging and analysis capabilities adjacent to Lambda's Live&3D Imaging services.
  • Stemcell Technologies: Major life-science tools company providing organoid culture media, reagents, and supporting services used by organoid researchers globally. Comparable as an incumbent enabling the organoid research ecosystem with overlapping pharma and academic customer base, though operating in tools/reagents rather than CRO services.

Direct peers

  • Definigen: Provider of human iPSC-derived cell models and organoid services for drug discovery, with focus on liver, intestinal, and disease-specific models. Comparable as a specialty organoid CRO serving pharma and biotech with similar disease modeling and toxicity testing offerings.
  • InSphero: Swiss-based provider of 3D in vitro models including organoids, microtissues, and spheroids for drug safety and efficacy testing. Directly comparable as a specialty 3D in vitro CRO with overlapping pharma/biotech customer base and similar non-animal testing value proposition.
  • Crown Bioscience: Global CRO offering patient-derived xenograft (PDX) and organoid-based preclinical oncology services for pharma and biotech. Directly comparable to Lambda Biologics as both provide human-relevant in vitro/ex vivo tumor models for drug discovery, with overlapping customer base in immuno-oncology and ADC evaluation.
  • Hubrecht Organoid Technology (HUB): Pioneer in organoid technology with foundational patents around Lgr5+ stem-cell-derived organoids; offers organoid biobanking, disease modeling, and drug screening services. Directly comparable as a specialty organoid CRO with biobank and disease modeling offerings serving pharma and academic customers.

Emerging players

  • XCell Science: Provider of iPSC-derived neural and disease organoids for neuroscience drug discovery and toxicology. Comparable as a niche organoid CRO with overlap in disease modeling services (neural organoids), targeting similar pharma/biotech and academic customers in specialty indications.
  • Cellesce: UK-based company developing scalable organoid expansion technologies for drug discovery and disease modeling. Comparable as an emerging player in patient-derived organoid services with overlapping focus on biobank scalability and pharma partnerships.
  • Cypre Holdings: Developer of patient-derived tumor organoid platforms for high-throughput drug screening and predictive oncology. Comparable as an emerging player in patient-derived organoid services with overlapping pharma/biotech customer base and similar focus on translational drug response prediction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Lambda Biologics social profiles

Digital presence

Lambda Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lambda Biologics leadership team

Management profile

Number of profiles

Lambda Biologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lambda Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lambda Biologics

What does Lambda Biologics do?

Lambda Biologics is a contract research organization providing organoid-based in vitro drug evaluation services and disease modeling. It supplies patient-derived normal and cancer organoids, custom organoid co-culture assays with immune and stromal cells, and analytical services (molecular biology, bioinformatics, spatial biology, live 3D imaging), delivered through direct project engagements quoted via its MyLab platform.

Is Lambda Biologics a public or private company?

Lambda Biologics is a private company. It is classified as unknown and is currently operating.

When was Lambda Biologics founded?

Lambda Biologics was founded in -1. It employs 1 to 10 people.

Where is Lambda Biologics based?

Lambda Biologics is headquartered in Leipzig, Germany, in the Europe region.

How does Lambda Biologics make money?

Two revenue lines are on record. Organoid Services and Research is the primary driver. The others are organoid Banking System.

Who are Lambda Biologics's main competitors?

Broad incumbents on record are Charles River Laboratories, Molecular Devices (Danaher) and Stemcell Technologies. Direct peers are Definigen, InSphero, Crown Bioscience and Hubrecht Organoid Technology (HUB). Emerging players are XCell Science, Cellesce and Cypre Holdings.

Does Lambda Biologics have an API?

No public API is recorded for Lambda Biologics.

What industry is Lambda Biologics in?

Lambda Biologics's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales